Clinical Characteristics of Patients with Autoimmune Pancreatitis with or without Mikulicz’s Disease and Mikulicz’s Disease Alone
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The objective of this study was to compare the clinical characteristics of patients with autoimmune pancreatitis (AIP) with or without Mikulicz’s disease (MD) and with MD alone. Methods: We investigated the clinical findings in 15 AIP patients with MD (group A+M), 49 AIP only patients (group A), and 14 MD only patients (group M). Results: The male-female ratio was significantly higher in group A+M (73%, p<0.05) and group A (78%, p<0.01) than group M (21%). Serum immunoglobulin G (IgG) levels were significantly higher in group A+M than in group A (p<0.01) and group M (p<0.05). Serum IgG4 levels were significantly higher in group A+M than in group A (p<0.01). Other organ involvement was observed in 73% (11/15) of patients in group A+M. The number of patients with diabetes mellitus was significantly higher in group A+M (66%, p<0.01) and group A (51%, p<0.05) than in group M (7%). All of the patients responded well to steroid therapy, but the relapse rate in group A+M (33%) was significantly higher than that in group A (3%, p<0.01). Salivary gland function was impaired in all groups compared with the control group, but the degree of dysfunction was less in group A compared with group A+M and group M. Conclusions: The relapse rate of AIP in MD patients was significantly higher than that of AIP in patients without MD.
Abstract
Background/Aims: The objective of this study was to compare the clinical characteristics of patients with autoimmune pancreatitis (AIP) with or without Mikulicz’s disease (MD) and with MD alone. Methods: We investigated the clinical findings in 15 AIP patients with MD (group A+M), 49 AIP only patients (group A), and 14 MD only patients (group M). Results: The male-female ratio was significantly higher in group A+M (73%, p<0.05) and group A (78%, p<0.01) than group M (21%). Serum immunoglobulin G (IgG) levels were significantly higher in group A+M than in group A (p<0.01) and group M (p<0.05). Serum IgG4 levels were significantly higher in group A+M than in group A (p<0.01). Other organ involvement was observed in 73% (11/15) of patients in group A+M. The number of patients with diabetes mellitus was significantly higher in group A+M (66%, p<0.01) and group A (51%, p<0.05) than in group M (7%). All of the patients responded well to steroid therapy, but the relapse rate in group A+M (33%) was significantly higher than that in group A (3%, p<0.01). Salivary gland function was impaired in all groups compared with the control group, but the degree of dysfunction was less in group A compared with group A+M and group M. Conclusions: The relapse rate of AIP in MD patients was significantly higher than that of AIP in patients without MD.
참고문헌 (21)
- Billroth GT, "Beitr Chir Fortschr", pp.610~630 (1892)
- Morgan WS, "A clinicopathologic study of Mikulicz’s disease", Am J Pathol, 29, pp.471~503 (1953)
- Yamamoto M, "Clinical and pathological differences between Mikulicz’s disease and Sjogren’s syndrome", Rheumatology (Oxford), 44, pp.227~234 (2005)
- Yamamoto M, "A new conceptualization for Mikulicz’s disease as an IgG4-related plasmacytic disease", Mod Rheumatol, 16, pp.335~340 (2006)
- Umehara H, "A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details", Mod Rheumatol, 22, pp.1~14 (2012)
- Kamisawa T, "Autoimmune pancreatitis and IgG4-related sclerosing disease", Nat Rev Gastroenterol Hepatol, 7, pp.401~409 (2010)
- Kamisawa T, "A new clinicopathological entity of IgG4-related autoimmune disease", J Gastroenterol, 38, pp.982~984 (2003)
- Kamisawa T, "Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease", J Gastroenterol, 41, pp.613~625 (2006)
- Otsuki M, "Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis", J Gastroenterol, 43, pp.403~408 (2008)
- Masaki Y, "IgG4-related diseases including Mikulicz’s disease and sclerosing pancreatitis: diagnostic insights", J Rheumatol, 37, pp.1380~1385 (2010)
- Kamisawa T, "Japanese consensus guidelines for management of autoimmune pancreatitis: III. treatment and prognosis of AIP", J Gastroenterol, 45, pp.471~477 (2010)
- Kamisawa T, "Standard steroid treatment for autoimmune pancreatitis", Gut, 58, pp.1504~1507 (2009)
- Kamisawa T, "Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy", Pancreas, 27, pp.235~238 (2003)
- Kamisawa T, "The relationship of salivary gland function to elevated serum IgG4 in autoimmune pancreatitis", Intern Med, 46, pp.435~439 (2007)
- Hamano H, "Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis", J Gastroenterol, 41, pp.1197~1205 (2006)
- Kamisawa T, "Serum IgG4 levels and extrapancreatic lesions in autoimmune pancreatitis", Eur J Gastroenterol Hepatol, 20, pp.1167~1170 (2008)
- Ghazale A, "Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer", Am J Gastroenterol, 102, pp.1646~1653 (2007)
- Tanaka S, "Corticosteroid-responsive diabetes mellitus associated with autoimmune pancreatitis", Lancet, 356, pp.910~911 (2000)
- Sah RP, "Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis", Gastroenterology, 139, pp.140~148 (2010)
- Takuma K, "Short-term and long-term outcomes of autoimmune pancreatitis", Eur J Gastroenterol Hepatol, 23, pp.146~152 (2011)
- Kubota K, "Highly active state of autoimmune pancreatitis with mikulicz disease", Pancreas, 39, pp.e6~e10 (2010)